Qiagen N.V. (QGEN)
Market Cap | 9.47B |
Revenue (ttm) | 1.96B |
Net Income (ttm) | 484.93M |
Shares Out | 228.04M |
EPS (ttm) | 2.12 |
PE Ratio | 28.63 |
Forward PE | 19.34 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 764,505 |
Open | 41.43 |
Previous Close | 41.45 |
Day's Range | 41.26 - 41.67 |
52-Week Range | 34.74 - 51.18 |
Beta | 0.43 |
Analysts | Buy |
Price Target | 50.50 (+21.66%) |
Earnings Date | Oct 30, 2023 |
About QGEN
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample mate... [Read more]
Financial Performance
In 2022, Qiagen's revenue was $2.14 billion, a decrease of -4.82% compared to the previous year's $2.25 billion. Earnings were $575.66 million, an increase of 7.19%.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for QGEN stock is "Buy." The 12-month stock price forecast is $50.5, which is an increase of 21.66% from the latest price.
News

DNA Labs International solves significant cold cases with QIAGEN workflow for forensic genetic genealogy
QIAGEN's ForenSeq Kintelligence System recently used by DNA Labs International in the U.S. to solve unidentified remains case in Oregon and 51-year-old criminal investigation in Georgia // ForenSeq Ki...

QIAGEN launches TissueLyser III and RNeasy PowerMax Soil Pro Kit for improved sample processing and RNA isolation
TissueLyser III bead mill instrument can be used to effectively disrupt samples such as bones, as well as animal and plant tissue to enable access to nucleic acids // TissueLyser III enhances QIAGEN p...

QIAGEN launches new QIAcuity digital PCR kits and updated software to expand use by biopharma and food safety customers
Three new QIAcuity kits enhance digital PCR applications in biopharma research and food safety, ensuring precise quantification, increased sensitivity and cost-efficiency // QIAcuity Software 2.5 upda...

QIAGEN launches complete Sample to Insight workflow for microbiome research
Simplified and accelerated research workflow including high-quality DNA extraction kits, library preparation for whole genome metagenomics, and user-friendly bioinformatics analysis // Workflow enable...

QIAGEN and Element Biosciences partner to offer complete next-generation sequencing workflows for the AVITI System
Partnership combines QIAGEN's QIAseq panels, CLC LightSpeed, and QCI Interpret software to support Element's AVITI System users in genomic analysis Element and QIAGEN are advancing genomic application...

QIAGEN exceeds outlook for Q3 2023 with 5% CER sales growth in non-COVID products and adjusted EPS of $0.50 CER
Q3 2023: Net sales of $476 million (-5% at actual rates, -6% at constant exchange rates, CER); diluted EPS of $0.34 and adjusted diluted EPS of $0.50 // Net sales at CER of $470 million ahead of outlo...

QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer
Partnership covers development of lab-developed and distributable kit-based companion diagnostic tests // Combined strengths in assay development, clinical testing, and regulatory approvals offers pha...

QIAGEN N.V. to release results for Q3 2023 and hold webcast
Venlo, the Netherlands, Oct. 09, 2023 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the third quarter 2023.

QIAGEN launches QuantiFERON-EBV RUO assay, facilitating research of cell-mediated immune response to Epstein-Barr virus
QuantiFERON-EBV RUO to help researchers understand Epstein-Barr virus (EBV) infections and related malignancies, offering a dynamic view of the host immune response // Advancing research in oncology a...

QIAGEN extends AI capabilities of its NGS interpretation software QCI Interpret to enable clinical exome completeness
AI-driven literature extraction for thousands of rare disease genes fortifies and extends QIAGEN's proprietary, human-certified content, providing complete bibliographic coverage of the clinical exome...

QIAGEN's QuantiFERON solutions recommended for use by kidney specialists in Tunisia
TUNIS, Tunisia, Sept. 28, 2023 (GLOBE NEWSWIRE) -- QIAGEN today announced that the comprehensive QuantiFERON immune response blood tests have been recommended for use by clinicians in Tunisia to help ...

QIAGEN reports progress toward achieving Environmental, Social and Governance goals in 2022 Sustainability Report
Progress on Environment, Social and Governance (ESG) goals reflected in QIAGEN securing a „Prime“ rating and among the industry leaders with ISS-ESG rating // Environment: Net-zero target validated by...

QIAGEN enhances QIAwave portfolio with new eco-friendlier nucleic acid extraction kits
New kits reduce use of plastics by up to 62% and cardboard by up to 58% compared to QIAGEN standard kits // Two additions to growing QIAwave portfolio: QIAwave RNeasy Plus Mini Kit and QIAwave DNA/RNA...

QIAGEN delivers ahead of outlook for Q2 2023 with 9% CER sales growth in non-COVID products and updates 2023 full-year outlook
Q2 2023: Net sales of $495 million (-4% at actual rates, -4% at constant exchange rates, CER); diluted EPS of $0.35 and adjusted diluted EPS of $0.51 // Net sales at CER of $497 million ahead of outlo...

QIAGEN receives FDA approval for companion diagnostic to Blueprint Medicines' AYVAKIT® (avapritinib) in gastrointestinal stromal tumors
QIAGEN's therascreen PDGFRA RGQ PCR kit approved in U.S. to aid in identifying patients with unresectable or metastatic gastrointestinal stromal tumors positive for the PDGFRA D842V mutation who may b...

Bio-Rad and QIAGEN announce patent settlement and cross-licensing agreement
Hercules, Calif., and Venlo, the Netherlands, July 26, 2023 (GLOBE NEWSWIRE) -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announ...

Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement
HERCULES, Calif., & VENLO, the Netherlands--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), today announced that the compa...

QIAGEN N.V. to release results for Q2 2023 and hold webcast
Venlo, The Netherlands, July 24, 2023 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the second quarter 2023.

QIAGEN expands range of digital PCR kits and services for the biopharma industry
New partnership with Niba Labs to offer customized digital PCR (dPCR) assay design services to biopharma customers // Launch of CGT Viral Vector Lysis Kit enabling standardized workflow from cell lysa...

FBI approves QIAGEN's NGS-based ForenSeq MainstAY workflow for the U.S. National DNA Index System (NDIS)
NDIS approval provides access to federal government funding for accredited public crime laboratories in the U.S. to implement next-generation sequencing (NGS) for routine casework // NGS-based ForenSe...

QIAGEN provides reminder on settlement mechanics of 2023 and 2024 convertible notes
Venlo, the Netherlands, June 16, 2023 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today a notice (reiterating its notice to holders dated January 9, 2019) to ...

QIAGEN's QuantiFERON-TB Gold Plus shows unique clinical value with CD8 technology in new meta-analysis of tuberculosis screening
First-of-its-kind systematic review on the clinical relevance of test values from the QuantiFERON-TB Gold Plus TB1 and TB2 blood collection tubes has been published // Study including 4,050 subjects h...

Danish National Genome Center selects QIAGEN for variant interpretation in oncology genome sequencing
Denmark one of the first countries to implement whole-genome sequencing (WGS) as a standard-of-care for oncology and to adopt QCI Interpret to support the national initiative // QCI Interpret to be us...

QIAGEN exceeds outlook for Q1 2023 with 12% CER sales growth in non-COVID product portfolio
Q1 2023: Net sales of $485 million (-23% at actual rates, -20% at constant exchange rates, CER); diluted EPS of $0.37 and adjusted diluted EPS of $0.51 // Net sales at CER of $502 million ahead of out...

QIAGEN welcomes U.S. Preventive Services Task Force reaffirmation for latent TB screening in populations at increased risk
Venlo, the Netherlands, and Germantown, Maryland, May 03, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it welcomed the U.S. Preventive Services Task...